ArticleCancer research2013
Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Trial
- Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection.The Journal of thoracic and cardiovascular surgery · 2015Trial
- Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment.Molecules (Basel, Switzerland) · 2024Article
- Recent advances in ratiometric fluorescence imaging of enzyme activity in vivo.Current opinion in chemical biology · 2024Review
- Ratiometric near-infrared fluorescent probe for nitroreductase activity enables 3D imaging of hypoxic cells within intact tumor spheroids.Chemical science · 2024Article
- Review
- Multiscale profiling of protease activity in cancer.Nature communications · 2022Article
- Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy.Nature communications · 2022Article
- Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.Angewandte Chemie (International ed. in English) · 2022Article
- Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2022Article
- Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors.Nature biomedical engineering · 2022Article
- Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.Tissue barriers · 2022Review
- Let's embrace optical imaging: a growing branch on the clinical molecular imaging tree.European journal of nuclear medicine and molecular imaging · 2021Article
- Near-Infrared Fluorescent Probes for the Detection of Cancer-Associated Proteases.ACS chemical biology · 2021Review
- Prospect of cell penetrating peptides in stem cell tracking.Stem cell research & therapy · 2021Review
- Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.Pharmaceutics · 2021Article
- Activatable cell-penetrating peptides: 15 years of research.RSC chemical biology · 2020Review
- Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.Biomaterials · 2020Article
- Activity-Based Diagnostics: An Emerging Paradigm for Disease Detection and Monitoring.Trends in molecular medicine · 2020Review
- The impact of tumour pH on cancer progression: strategies for clinical intervention.Exploration of targeted anti-tumor therapy · 2020Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Management of metastatic disease is integral to cancer treatment. Evaluation of metastases often requires surgical removal of all anatomically susceptible lymph nodes for ex vivo pathologic examination. We report a family of novel ratiometric activatable cell-penetrating peptides, which contain Cy5 as far red fluorescent donor and Cy7 as near-infrared fluorescent acceptor. Cy5 is quenched in favor of Cy7 re-emission until the intervening linker is cut by tumor-associated matrix metalloproteinases-2 and 9 (MMP2,9) or elastases. Such cleavage increases the Cy5:Cy7 emission ratio 40-fold and triggers tissue retention of the Cy5-containing fragment. This ratiometric increase provides an accelerated and quantifiable metric to identify primary tumors and metastases to liver and lymph nodes with increased sensitivity and specificity. This technique represents a significant advance over existing nonratiometric protease sensors and sentinel lymph node detection methods, which give no information about cancer invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.